Literature DB >> 30342596

Intestinal microbiota in short bowel syndrome.

Hannah G Piper1.   

Abstract

Children with short bowel syndrome have significant changes to their intestinal microbiota after intestinal loss. The purpose of this article is to understand the potential implications of these changes on gut function, hepatic cholestasis and overall nutrition. Possible therapies to restore the commensal bacterial community in these patients will also be reviewed.
Copyright © 2018. Published by Elsevier Inc.

Entities:  

Keywords:  Dysbiosis; Intestinal microbiota; Prebiotics; Probiotics; Short bowel syndrome

Mesh：

Substances：

Year:  2018        PMID： 30342596     DOI： 10.1053/j.sempedsurg.2018.07.007

Source DB:  PubMed          Journal:  Semin Pediatr Surg        ISSN： 1055-8586            Impact factor:   2.754


  5 in total

Review 1.  Nutritional and pharmacological strategy in children with short bowel syndrome.

Authors:  Michael E Höllwarth; Valeria Solari
Journal:  Pediatr Surg Int       Date:  2021-01-03       Impact factor: 1.827

2.  Dietary fiber-based regulation of bile salt hydrolase activity in the gut microbiota and its relevance to human disease.

Authors:  Arthur Kastl; Wenjing Zong; Victoria M Gershuni; Elliot S Friedman; Ceylan Tanes; Adoma Boateng; William J Mitchell; Kathleen O'Connor; Kyle Bittinger; Natalie A Terry; Christina Bales; Lindsey Albenberg; Gary D Wu
Journal:  Gut Microbes       Date:  2022 Jan-Dec

Review 3.  Small Intestinal Bacterial Overgrowth in Children: A State-Of-The-Art Review.

Authors:  David Avelar Rodriguez; Paul MacDaragh Ryan; Erick Manuel Toro Monjaraz; Jaime Alfonso Ramirez Mayans; Eamonn Martin Quigley
Journal:  Front Pediatr       Date:  2019-09-04       Impact factor: 3.418

4.  Jejunoileal mucosal growth in mice with a limited microbiome.

Authors:  Matthew P Shaughnessy; Christine J Park; Pooja S Salvi; Robert A Cowles
Journal:  PLoS One       Date:  2022-03-29       Impact factor: 3.240

5.  Therapeutic potential of an intestinotrophic hormone, glucagon-like peptide 2, for treatment of type 2 short bowel syndrome rats with intestinal bacterial and fungal dysbiosis.

Authors:  Xiuting Hu; Wei Cheng; Shengxian Fan; Yuhua Huang; Xi Chen; Zhiwei Jiang; Jian Wang
Journal:  BMC Infect Dis       Date:  2021-06-16       Impact factor: 3.090
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.